Asia Pacific Clinical Trials Market – Size, Outlook, Trends and Forecast (2024 – 2032)

A clinical trial management system (CTMS) is a system used by Pharmaceutical and Biotechnology industries to manage clinical trials in clinical research. The system maintains and oversees the planning, performing and reporting functions, along with participant contact information, tracking deadlines and many more.

Asia-Pacific Clinical Trials Market Segments Size & Growth:

Asia-Pacific clinical trials market size is projected to reach approximately $5.2 billion by the end of 2024 with a CAGR of close to 9.1% from $ 3.50 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increased R&D investment in the Pharmaceutical industry, Increased prevalence of chronic diseases, Increased clinical research outsourcing and implementation of clinical trials by contract research organisations and Assimilation of clinical trial management systems with hospital information systems. However, High cost involved in customised CTMS, Increasing clinical trials failure rate in phase II and Phase III, Lack of qualified and skilled labour to handle CTMS and Data security issues are thereby hampering the market growth.

Asia-Pacific Clinical Trials Market Segments Share:

Asia-Pacific Clinical Trials Market is categorised into Phases which comprise of Phase I, Phase II, Phase III, Phase IV. By Design, The market is segmented into Observational Studies and Treatment Studies. By Geography, India and China are projected to dominate the market with the most significant share and the growth in the Asia Pacific economies is mainly attributed because of initiatives from the government and contributions from academic laboratories, which helped augment growth. Due to a large population in this region, it helps in faster enrollment of the patients, and retention of the participants in the trials on the higher side; thereby helping the companies to conduct the trials on the timely basis.

Asia-Pacific Clinical Trials Market Trends:

• To reduce cost pressures is to shift clinical trials to lower-cost areas. Globalizing clinical research provides CROs with an opportunity to run clinical trials efficiently and at a lower cost.
• Another trend that is fast evolving is to go paperless and increase the acceptance of electronic records. A novel drug application has hundreds and thousands of paper records. Adopting electronic records has made searching and analysis easier and also improved efficiencies of other initiatives to lower the costs of development and data management in clinical trials.
• LabCorp announced that they are acquiring Chiltern for approximately $1.3 billion in cash for advancing its leadership in drug development.

South America Clinical Trials Market Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
• Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• The primary market players, such as
• Chiltern
• Omnicare
• PPD
• Parexel
• Kendle